CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
Exenatide +1 moredrug
Likely dose
Exenatide 5 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01136798
NCT01136798N/ACompleted
CompareCT.gov

Impact of Exenatide on Sleep and Circadian Function in Type 2 Diabetes: A Pilot Study

University of Chicago·interventional·Posted Jun 3, 2010·Updated Sep 12, 2018

In Brief

A clinical study evaluating Exenatide and Placebo for Type 2 Diabetes and Sleep Disordered Breathing. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

The investigators propose a pilot study to test the novel hypothesis that Exenatide treatment in patients with type 2 diabetes results in improved sleep duration and quality and to explore the relationship between improvements in sleep and measures of metabolic and circadian function. This project would be the first to probe the relationship between incretin hormone regulation, duration and intensity of sleep, glucose tolerance and circadian dysfunction in diabetic patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Sleep Disordered Breathing
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 3, 2010
Enrollment StartJun 1, 2010
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 16.1 years ago

Interventions

Exenatidedrug

Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks

Placebodrug

Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks